Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6

Authors:

Abstract
Objective Optimal targeted treatment in rheumatoid arthritis requires early identification of failure to respond. This post‐hoc analysis explored the relationship between early disease activity changes and achievement of low disease activity (LDA) and remission targets with tofacitinib. Methods Data were from two randomized, double‐blind, Phase 3 studies. In ORAL Start (NCT01039688), methotrexate (MTX)‐naïve patients received tofacitinib 5 or 10 mg BID, or MTX, for 24 months. In placebo‐controlled ORAL Standard (NCT00853385), MTX‐inadequate responder (MTX‐IR) patients received tofacitinib 5 or 10 mg BID or adalimumab 40 mg Q2W, with MTX, for 12 months. Probabilities of achieving LDA (CDAI ≤10; DAS28‐4[ESR] ≤3.2) at months 6 and 12 were calculated, given failure to achieve threshold improvement from baseline (change in CDAI ≥6; DAS28‐4[ESR] ≥1.2) at month 1 or 3. Results In ORAL Start, 7.2% and 5.4% of patients receiving tofacitinib 5 and 10 mg BID, respectively, failed to improve CDAI ≥6 at month 3; of those who failed, 3.8% and 28.6%, respectively, achieved month 6 CDAI‐defined LDA. In ORAL Standard, 18.8% and 17.5% of patients receiving tofacitinib 5 and 10 mg BID, respectively, failed to improve CDAI ≥6 at month 3; of those who failed, 0% and 2.9%, respectively, achieved month 6 CDAI‐defined LDA. Findings were similar when considering month 1 improvements or DAS28‐4(ESR) thresholds. Conclusions In MTX‐IR patients, lack of response to tofacitinib after 1 or 3 months predicted low probability of achieving LDA at month 6. Lack of early response may be considered when deciding whether to continue treatment with tofacitinib.
Funding Information
  • Pfizer

This publication has 29 references indexed in Scilit: